ArticleThe Australian & New Zealand journal of obstetrics & gynaecology2026
Modelling Maternal Cytomegalovirus Seroprevalence in Australia Using Maternal Country of Birth: Implications for Antenatal Screening.
Article in The Australian & New Zealand journal of obstetrics & gynaecology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytomegalovirus in pregnancy: prevention, maternal screening, and the role of antivirals.Australian prescriber · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCytomegalovirus (CMV) is the most common congenital infection and a leading preventable cause of neurodevelopmental disability. Contemporary maternal CMV seroprevalence estimates are needed to inform antenatal screening policy in Australia. PURPOSE: To estimate CMV seroprevalence among women referred for antenatal care at a tertiary maternity hospital, identify clinical and sociodemographic associations with serostatus, and model national and hospital-level seroprevalence by maternal country of birth. MATERIALS AND
methodsCMV serology results from GP antenatal referrals to a Melbourne tertiary hospital over 13 months were analysed. Seroprevalence was stratified by maternal country of birth, grouped by Organisation for Economic Co-operation and Development (OECD) membership. National and hospital-specific seroprevalence were modelled using Australian Bureau of Statistics and research dataset country-of-birth distributions.
resultsOf 4377 referrals, 591 (12.5%) included CMV serology; 61.3% were CMV IgG positive. Median gestational age at testing was 5.4 weeks; referral occurred at a median of 9 weeks. Seroprevalence was higher among women born in non-OECD countries (86.6%) versus OECD countries (54.3%) (adjusted OR 6.44, p < 0.001). Modelled national maternal seroprevalence was 63.6%. Across Melbourne public hospitals, estimates ranged from 60% to 74%, reflecting demographic variation. Among 328 women tested for CMV IgM, 17 (5.2%) had positive or equivocal results; one had low avidity IgG, consistent with recent primary infection.
conclusionsMaternal CMV seroprevalence in this cohort is higher than previously reported and strongly associated with maternal country of birth. These data inform evaluation of antenatal CMV screening feasibility and cost-effectiveness studies in Australia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.